Lymph Node Ratio Predicts Long-Term Survival in Lymph Node-Positive Breast Cancer

Ayşegül Sakin¹ D, Mehmet Naci Aldemir² D

¹Department of Internal medicine, University of Health Sciences, Van Research and Training Hospital, Van, Turkey ²Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Van, Turkey

ABSTRACT

Objective: In this study, we aimed to evaluate the prognostic value of axillary lymph node ratio (LNR) for disease-free survival (DFS) in node positive breast cancer (BC) patients with long term follow-up.

Materials and Methods: A total of 179 stage II to III female BC patients, who were followed between December 2001 and January 2019 at the department of medical oncology, were included in this study. Patients were classified into 3 groups based on the LNR as follows; LNR<0.21, LNR=0.21-0.65, and LNR>0.65. SPSS 22 for windows was used for statistical analysis.

Results: The median age was 49 (range, 24-83) years. The numbers of patients with stage II and stage III disease were 81 (45.3%) and 98 (54.7%), respectively. The median number of lymph node (LN) resected and positive LN were 15 (range, 3-48) and 3 (range, 1-29), respectively. There were 90 patients (50.3%) with LNR <0.21, 62 (34.6%) with LNR=0.21-0.65, and 27 (15.1%) with LNR >0.65. The median disease-free survival (DFS) was not reached in patients with LNR <0.21, 81 months in patients with LNR=0.21-0.65, and 43 months in patients with LNR>0.65 (p<0.001). Overall survival (OS) was found to be significantly related to LNR (p=0.042). In patients with LNR<0.21 and LNR=0.21-0.65, the median OS was not reached. In patients with LNR >0.65, the median OS was 101 months. In multivariate analysis, LNR=0.21-0.65 (Hazard ratio [HR], 6.99), LNR>0.65 (HR, 28.99), and HER-2 negativity (HR, 4.64) were the factors associated with DFS (p<0.05).

Conclusion: LNR is a more useful prognostic factor than the pathological lymph node staging for predicting survival in patients with nod-positive BC. **Keywords:** Breast cancer, lymph node ratio, survival

Cite this articles as: Sakin A, Aldemir MN. Lymph Node Ratio Predicts Long-Term Survival in Lymph Node-Positive Breast Cancer. Eur J Breast Health 2020; 16(4): 270-275.

Introduction

Globally, breast cancer (BC) is the most commonly diagnosed cancer in women as well as being one of the most common cancer-related deaths, particularly in patients aged 40-49 years (1,2). Its treatment requires a multidisciplinary team approach which includes surgical oncology, medical oncology, and radiation oncology. The majority of BC patients are diagnosed at non-metastatic stage. Approximately 5% of patients have metastatic disease at the time of diagnosis (2, 3). For BC patients, the treatment decision depends on some factors including disease stage, hormone receptor status, and human epidermal growth factor receptor- 2 (HER-2) status at presentation (1-3).

It is well-known that locoregional radiotherapy to axillary lymph nodes (ALN) has decreased local recurrence and improved survival in node-positive BC. The ALN status has been considered a possible indication for post-surgical adjuvant radiotherapy. However, it may depend on the degree of ALN resected. Moreover, in some cases, the decision regarding whether radiotherapy is necessary depends on the physician (4-6).

The lymph node ratio (LNR) is described as the ratio of number of positive ALN to total number of ALN resected. Truong et al. (7) included 80 BC patients with 1 to 3 ALN positive and reported that LNR was related to an increased locoregional recurrence and also a stronger prognostic factor than the number of positive ALN. Similarly, Han et al. (8) included 130 BC patients with N1 stage and reported that LNR was associated with an increased risk of recurrence, especially in younger BC patients.

A study performed by Kuru (9) who analyzed 801 BC patients showed that the number of ALN resected >15 or number of negative ALN >15 improved survival. ALN status continues to be one of the main prognostic factors guiding the adjuvant radiotherapy decision. pN stage is based on the number of ALN resected. However, the accuracy of the approach is affected by the number of ALN resected, which

may cause undesirable results (10, 11). In this retrospective study, we aimed to evaluate the prognostic value of LNR in ALN-positive BC patients on long-term outcomes.

Materials and Methods

Study population

A total of 179 stage II to III female BC patients, who were followed between December 2001 and January 2019 at the department of medical oncology, Yüzüncü Yıl University Faculty of Medicine, were included in this study. All patients had unilateral BC, with non-metastatic disease at initial presentation. ALN dissection was performed in all patients at the time of diagnosis. Patients were restaged based on the 8th edition of the American Joint Committee on Cancer staging system. Patients with any of the following criteria were excluded from the study; <18 years of age, metastatic stage, unoperated patients, receiving neoadjuvant treatment, history of a second primary cancer, histologic subtypes other than invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), and patients whose data were not available. The study was performed in accordance with the Helsinki Declaration and was approved by the Yüzüncü Yıl University Faculty of Medicine Ethics Committee (22/05/2020-2020/03-54).

Data collection

Demographic data including age, menopausal status (perimenopause vs. postmenopausal), type of surgery (breast-conserving surgery [BCS] vs. modified radical mastectomy [MRM]), hormone-receptor status, HER2-status, histology (IDC or ILC), stage, grade, perineural invasion, lymphovascular invasion, pathological tumor stage (pT), number of ALN resected, number of positive ALN, margin status, adjuvant chemotherapy, hormonotherapy and radiotherapy, recurrence and site of recurrence, and final status (exitus or alive) were obtained from the written archive files. LNR was calculated by the ratio of number of positive ALN to total number of ALN resected. The classifications of LNR were based on the previous studies which divided the LNR into 3 categories as follows; LNR <0.21, LNR=0.21-0.65, and LNR >0.65 (12, 13). pT stage was stratified into 2 groups as pT1-2 and pT3-4. Tumor grade was grouped into 2 categories as grade 1-2 and grade 3. Disease-free survival (DFS) was calculated as the time from the date of diagnosis to the date of recurrence or last control. Overall survival (OS) was estimated from the date of diagnosis to the date of death or last follow-up.

Key Points

- Axillary lymph nodes (ALN) status has been considered a possible indication for post-surgical adjuvant radiotherapy. However, the accuracy of the approach is affected by the number of ALN resected, which may cause undesirable results.
- The lymph node ratio (LNR) is described as the ratio of the number positive ALN to the total number of ALN resected. In this study, we evaluated the prognostic value of LNR in ALN-positive breast cancer (BC).
- Disease-free survival and overall survival were found to be significantly related to LNR.
- The LNR is an independent prognostic factor of disease-free survival and pN staging lost its significance when LNR was added to the multivariate analysis.
- LNR is a more useful prognostic factor than the pathological lymph node staging for predicting survival in operated stage II-III BC patients.

Statistical analysis

IBM Statistical Package for Social Sciences (IBM SPSS Corp.; Armonk, NY, USA) 22 for windows was used. Chi-square analysis was carried out to compare the ratios in the groups. Survival analysis was performed using Kaplan-Meier method, and Log-rank test was used for comparison of survival time. The independent prognostic factors for survival were identified by Cox Regression Analysis. Forward stepwise model was used for the factors with p<0.150, which were determined in univariate analysis. Statistical significance value was accepted as p<0.05.

Results

The median age of the patients were 49 years (range, 24–83). Of the 179 patients, 171 (84.4%) were hormone-receptor positive and 30 (17.3%) were HER-2 positive. Nine (5%) patients were triple negative. Eighty-one patients (45.3%) had stage II disease and 98 patients (54.7%) had stage III disease. The median number of ALN resected and positive ALN were 15 (3-48) and 3 (1-29), respectively. There were 90 (50.3%) patients with LNR <0.21, 62 (34.6%) with LNR 0.21-0.65, and 27 (15.1%) with LNR >0.65 (Table 1).

All patients received adjuvant chemotherapy following surgery. A total of 137 (76.5%) patients received doxorubicin + taxane-based chemotherapy regimen, 38 (21.2%) patients received doxorubicin-based chemotherapy regimen. and 4 (2.2%) patients received taxane-based chemotherapy regimen. Thirty (16.8%) patients received trastuzumab. Radiotherapy was given to 171 (95.5%) patients. Hormone receptorpositive patients received adjuvant endocrine therapy after the completion of chemotherapy and radiotherapy. During the median followup time of 36 months, 32 (17.9%) patients developed recurrence, 8 (4.5%) of whom died (Table 1).

In Kaplan Meier analysis, the LNR was found to be significantly associated with DFS (log rank p<0.001). The median DFS was not reached in the patients with LNR<0.21, 81 months (95% confidence interval [CI], 59.0-102.9) in patients with LNR=0.21-0.65 patients, and 43 months (95 % CI, 12.6-74.4) in patients with LNR >0.65 (Figure 1).

OS was significantly associated with LNR (log rank p=0.042). The median OS was not reached in the patients with LNR<0.21 and




Figure 1. Disease- free Survival (DFS) according to LNR groups

Table 1. Patient characteristics

Age Menopausi statusMedian (Min-Max)49 (24-83)Menopausi statusPost-9251.4Surgical statusMRM11463.7BCS6536.316.1Hormone-receptor statusPositive3017.3HER2-statusPositive3017.3TNCBYes95.0HistologyIDC16592.2ILC147.8StageII8145.3III9854.7GradeIII15269.8III15375.4Positive13575.4Positive13575.4Positive13659.2III5430.2Perineural invasionNegative135Positive14424.6Lymphovascular invasionNegative7340.8Positive14452.111.2Lymphode removedMedian (Min-Max)15 (1-2.9)Pi-stage1-39150.8Ling2102815.6Link0.21.0.652715.1Margin statusPositive95.0Adjuvant ChemotherapyYes16.830.2Adjuvant chemotherapyYes3214.8Adjuvant chemotherapyYes329.4Adjuvant chemotherapyYes329.4Adjuvant chemotherapyYes329.4Adjuvant chemotherapyYes32 <td< th=""><th>Variable</th><th></th><th>n</th><th>%</th></td<>	Variable		n	%
Pre-8786.6Surgial statusMRM1146.37MRM15280.4Hicronereceptor statusPositive301.7.3HER2-statusPositive95.0HistologyIDC16592.2ILC147.8StageII8145.3II9854.7GradeIII9854.7III9854.7GradeHII12569.8III5460.2Perineural invasionNegative1357.54Positive10659.2PT-stage17-21347.8Positive10659.2PT-stage17-21347.9Positive10659.2PT-stage17-340.8Positive15 (3-48)7.4Metatus lymph node removedMedian (Min-Max)15 (3-48)LNR0.21-0.65273.5LNR0.21-0.65273.5LNR0.21-0.65273.5Adjuvant trasturumabYes3016.8Adjuvant trasturumabYes3016.8Adjuvant trasturumabYes3016.8Adjuvant RadiotherapyYes3217.9Adjuvant RadiotherapyYes3217.9Adjuvant RadiotherapyYes3217.9Adjuvant RadiotherapyYes3217.9Adjuvant RadiotherapyYes<	Age	Median (Min-Max)	49 (24-83)	
Surgical statusMRM1146.3.7BCS6536.3Hormone-receptor statusPositive3017.3TNCBYes950HistologyIDC16.592.2LC147.853.6StageII8145.3GradeHHI12.566.8III9854.7GradeHI5430.2Perineural invasionNegative7.340.8Positive4424.6Lymphovascular invasionNegative7.340.8Positive10.659.25.1Lymphovascular invasionNegative7.340.8Positive44.525.15.1Lymph node removedMedian (Min-Max)11.2156Lymph node removedMedian (Min-Max)31.55.1Lymph node removed1.39.150.8Adjuvant ChemotherapyPositive95.0Adjuvant ChemotherapyPositive95.0Adjuvant ChemotherapyYes3.016.8Adjuvant RadiotherapyYes3.217.9Vesurifican in Faxane7.650.07.6Adjuvant RadiotherapyYes3.217.9Recurrence and localizationYes3.217.9Narifen7.650.05.2Recurrence and localizationYes3.217.9Narifen7.650.05.2Adjuvant Radiother	Menopausal status	Post-	92	51.4
BCS6536.3Hormone-receptor statusPositive15280.4HER2-statusPositive307.3TNCBYes95.0HistologyDC16592.2LC147.8StageII8145.3GradeII985.47GradeIII12569.8III985.47GradeIII13575.4Prineural invasionNegative13575.4Positive10659.2PT-stage17.213474.9Pt-stage17.44559.2Pt-stage17.44559.2Pt-stage17.44559.2Pt-stage17.4151.54-8)75.4Median (Min-Max)3 (1-29)50.350.3PN-stage1.39.150.8Adjuvant ChemotherapyPositive950.3Adjuvant ChemotherapyPositive950.4Adjuvant ChemotherapyYes13276.5Adjuvant RadiotherapyYes13776.5Adjuvant RadiotherapyYes15284.9Adjuvant RadiotherapyYes13276.5Recurrence and localizationYes327.9Ieoregional39.455Recurrence and localizationYes327.9Ieoregional39.455Recurrence and localizationYes32 </td <td></td> <td>Pre-</td> <td>87</td> <td>48.6</td>		Pre-	87	48.6
Hormone-receptor statusPositive15280.4HER2-statusPositive3017.3TNCBYes95.0HistologyIDC16592.2LC147.8StageII8145.3GradeHI12.569.8III5430.2Perineural invasionNegative13.57.4Positive4424.6Lymphovascular invasionPositive4424.6Lymphovascular invasionPositive15.37.4Prestage11.213.474.9Prestage13.445.92.1Prestage13.445.92.1Prestage13.431.17.4Prestage1.39150.8Aquivant ChemotedMedian (Min-Max)31.13.5Prestage1.39150.8Aquivant ChemotherapyPositive95.0Adjuvant ChemotherapyPositive95.0Adjuvant ChemotherapyYes3.016.8Adjuvant RadiotherapyYes3.016.8Adjuvant RadiotherapyYes3.217.9Recurrence and localizationYes3.217.9Recurrence and localizationYes3.217.9Recurrence and localizationYes3.217.9Inanoxifen39.42.5Recurrence and localizationFes3.217.9Inanoxifen <t< td=""><td>Surgical status</td><td>MRM</td><td>114</td><td>63.7</td></t<>	Surgical status	MRM	114	63.7
HER2-status Positive 30 17.3 TNCB Yes 9 5.0 Histology IDC 165 92.2 Histology IDC 165 92.0 Stage II 81 45.3 Orade III 98 54.7 Crade III 98 54.7 Orade III 98 54.7 Orade III 98 54.7 III 98 54.7 55.2 Princural invasion Negative 135 57.4 Positive 106 59.2 50.7 pT-stage 13.4 45 25.1 Lymph node removed Median (Min-Max) 31(1-29) 50.8 Metastatic lymph node Median (Min-Max) 31(1-29) 50.8 Q10 2.1 3.6 2.1 50.8 Q21-0.65 62 3.6 50.8 50.8 50.8 Adjuvant Chemotherapy Positive		BCS	65	36.3
TNCBYes95.0HistologyIDC16592.2ILC147898StageII9854.7GradeHI12569.8III9854.7GradeNegative13575.4Perineural invasionNegative7340.8Positive4426.652.2pT-stageT1-213474.9T3-44525.1Lymph node removedMedian (Min-Max)15 (3-84)Netastatic (ymph node13575.4PN-stage1-39150.8LINR-0.219050.3Adjuvant ChemotherapyPositive95.0Adjuvant ChemotherapyPositive95.0Adjuvant trastuzumabYes13776.5Adjuvant kadiotherapyYes15284.9Adjuvant RadiotherapyYes15284.9Adjuvant RadiotherapyYes3271.9Narous RadiotherapyYes3271.9Adjuvant RadiotherapyYes3271.9Recurrence and localizationYes3271.9Final statusKitus84.5	Hormone-receptor status	Positive	152	80.4
HistologyIDC16592.2ILC147.8StageIL8145.1GradeIII8145.1GradeIII12.568.8III5430.2Perineural invasionNegative7340.8Perineural invasionNegative7445Perineural invasionNegative7450.8Adjuvant ChemotherapyPostive3068.8Adjuvant hormonotherapyYes15284.9Adjuvant hormonotherapyYes15284.9Adjuvant hormonotherapyYes3271.9Adjuvant RadiotherapyYes3271.9<	HER2-status	Positive	30	17.3
LC147.8StageII8145.3III9854.7GradeIII12569.8III5430.2Perineural invasionNegative13575.4Positive4424.6Lymphovascular invasionNegative7340.8Positive10659.2PT-tage73.447.9T1-213474.9Lymph node removedMedian (Min-Max)3 (1-29)PN-stage1-39150.8496033.52102815.6LNR4.96033.52102815.6LNR0.21-0.556234.6Adjuvant ChemotherapyPositive95.0Adjuvant ChemotherapyPositive95.0Adjuvant trastuzumabYes15284.9Adjuvant trastuzumabYes15284.9Adjuvant trastuzumabYes3016.8Adjuvant trastuzumabYes327.9Adjuvant trastuzumabYes327.9Adjuvant trastuzumabYes327.9Adjuvant trastuzumabYes327.9Adjuvant trastuzumabYes327.9Adjuvant trastuzumabYes327.9Adjuvant trastuzumabYes327.9Adjuvant trastuzumabYes327.9Adjuvant trastuzumabYes327.9<	ТИСВ	Yes	9	5.0
StageII8145.3III9854.7GradeHII12569.8III12569.8Perineural invasionNegative13575.4Positive4424.6Lymphovascular invasionNegative7340.8Positive10659.21pT-stageT1-213474.9Positive15335.11Lymph node removedMedian (Min-Max)15 (3-48)1Metastatic lymph nodeMedian (Min-Max)3 (1-29)1PN-stage1-39150.8LNR6033.516Adjuvant Chemotherapy0.652715.1Margin statusPositive95.0Adjuvant trastuzumabYes15234.9Adjuvant trastuzumabYes15234.9Adjuvant trastuzumabYes15234.9Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes37.934.9Iurog39.420.5Iuroge133.94.1Iuroge33.94.1Iuroge33.94.1Iuroge33.94.1Iuroge33.94.1Iuroge33.94.1Iuroge33.94.1Iuroge33.94.1Iuroge33.94.1Iuroge	Histology	IDC	165	92.2
III9854.7CradeI-II12569.8III5430.2Perineural invasionNegative13557.4Positive4424.6Lymphovascular invasionNegative7.340.8Positive10659.2pT-stage11-213445.9Lymph node removedMedian (Min-Max)15 (3-48)Metastatic lymph nodeMedian (Min-Max)3 (1-29)PN-stage1-39150.8Alphanee2.219050.3LNR0.21-0.652715.1Margin statusPositive95.0Adjuvant ChemotherapyPositive95.0Adjuvant trastuzumabYes15284.9Adjuvant hormonotherapyYes15284.9Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes3217.9Icocregional39.42.1Icoregional39.42.1Icoregional39.42.1Icoregional39.42.1Icoregional39.42.1Icoregional39.42.1Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5 </td <td></td> <td>ILC</td> <td>14</td> <td>7.8</td>		ILC	14	7.8
GradeHI12569.8III5430.2Perineural invasionNegative3575.4Lymphovascular invasionNegative7340.8Positive10659.2pTstageT1-213.474.9Lymph node removedMedian (Min-Max)15 (3-48)Metastatic lymph nodeMedian (Min-Max)3 (1-29)pN-stage1.39.150.8LNR4.96.033.5LNR0.52.715.1Adjuvant ChemotherapyPositive9.050.3Doxrubicin +Taxane13.776.5Adjuvant trastuzumabYes3.016.8Adjuvant trastuzumabYes3.016.8Adjuvant RadiotherapyYes7350.0Adjuvant RadiotherapyYes7350.0Adjuvant RadiotherapyYes7350.5Recurrence and localizationYes7350.5Recurrence and localizationYes3.064.5Icoregional39.412.5Icoregional39.412.5Icoregional39.412.5Icoregional39.412.5Icoregional39.4Icoregional39.4Icoregional39.4Icoregional39.4Icoregional39.4Icoregional39.4Icoregional39.4Icoregional <t< td=""><td>Stage</td><td>II</td><td>81</td><td>45.3</td></t<>	Stage	II	81	45.3
III5430.2Perineural invasionNegative13575.4Negative13575.4Lymphovascular invasionNegative7340.8Positive10659.2pT-stageT1-213474.9Lymph node removedMedian (Min-Max)15 (34.8)Wetastati (ymph nodeMedian (Min-Max)3(1-29)pN-stage1-39150.8LINR40.230.633.5LINR0.21-0.656234.6Nargin statusPositive950.3Adjuvant ChemotherapyPositive950.3Adjuvant trastuzumabYes3016.8Adjuvant trastuzumabYes3016.8Adjuvant RadiotherapyYes15234.9Adjuvant RadiotherapyYes7650.0Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes339.4Lung402062.5Liver39.4Ecoregional39.4Ecoregional39.4Ecoregional39.4Ecoregional39.4Ecoregional39.4Ecoregional39.4Ecoregional39.4Ecoregional39.4Ecoregional39.4Ecoregional39.4Ecoregional39.4Ecoregional39.4 <t< td=""><td></td><td>III</td><td>98</td><td>54.7</td></t<>		III	98	54.7
Perineural invasionNegative13575.4Positive4424.6Lymphovascular invasionNegative7340.8pTstage17-213459.2pTstage17-213474.9Lymph node removedMedian (Min-Max)15 (3-48)Metastatic lymph nodeMedian (Min-Max)3 (1-29)pN-stage1-39150.8A4.96033.5LNR6.0212815.6LNR0.652715.1Margin statusPositive950.3Adjuvant ChemotherapyDoxorubicin3821.2Doxorubicin +Taxane13776.5Adjuvant rastuzumabYes15284.9Adjuvant RadiotherapyYes15284.9Adjuvant RadiotherapyYes3217.9Recurrence and localizationYes3217.9Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional2	Grade	1+11	125	69.8
Positive4424.6Lymphovascular invasionNegative7340.8Positive10659.2pT-stage11-213.474.9T3-44525.1Lymph node removedMedian (Min-Max)3 (1-29)PN-stage1-39150.8pN-stage1-39150.8LNR-2102815.6LNR-0.652715.1Margin statusPositive95.0Adjuvant ChemotherapyPositive95.0Adjuvant ChemotherapyYes3016.8Adjuvant hormonotherapyYes3016.8Adjuvant kadiotherapyYes3016.8Adjuvant kadiotherapyYes3217.9Adjuvant kadiotherapyYes3217.9Keurrence and localizationYes3217.9Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.42.5Icoregional39.43.5Icoregional39.43.5Icoregional39.43.5<		III	54	30.2
Lymphovascular invasionNegative7340.8Positive10659.2pTstage11.213474.9Lymph node removedMedian (Min-Max)15 (3-48)Metastatic lymph nodeMedian (Min-Max)3 (1-29)pN-stage1-39150.8A96033.52102815.6LNR6.210.6556234.60.210.6556234.60.210.6556234.60.210.657715.1Margin statusPositive95.0Adjuvant ChemotherapyDoxorubicin +Taxane3016.8Adjuvant trastuzumabYes15284.9Adjuvant kadiotherapyYes15284.9Adjuvant kadiotherapyYes17195.5Recurrence and localizationYes3217.9Liver39.410.6Liver39.410.6Ling40.93.610.6Adjuvant kadiotherapyYes17.195.5Recurrence and localizationYes3.016.8Liver39.410.5Liver39.410.5Enance2062.510.6Liver39.410.5Enance2062.510.6Enance2062.510.6Enance39.410.5Enance39.410.5Enance39.4<	Perineural invasion	Negative	135	75.4
Positive10659.2pT-stageT1-2T3474.9T3-44525.1Lymph node removedMedian (Min-Max)T5 (3-48)Metastatic lymph nodeMedian (Min-Max)3 (1-29)pN-stage1-39150.82N2815.6LNR6033.52102815.62.10.656234.60.21.0.656234.60.21.0.656234.62.10.652715.1Margin statusPositive95.0Adjuvant ChemotherapyDoxorubicin3821.2Doxorubicin +Taxane13776.5Taxane42.2Adjuvant trastuzumabYes3016.8Adjuvant hormonotherapyYes15284.9Adjuvant hormonotherapyYes17195.5Recurrence and localizationYes3217.9Icoregional39.4Bone206.2Liver39.4Liver39.4Enain26.3Final statusExitus84.5		Positive	44	24.6
pT-stageT1-213474.9T3-44525.1Lymph node removedMedian (Min-Max)15 (3-48)Metastatic lymph nodeMedian (Min-Max)3 (1-29)pN-stage1-39150.8a 1-39150.84-96033.5LNR2815.6LNR0.219050.30.21-0.656234.6>0.652715.1Margin statusPositive95.0Adjuvant ChemotherapyDoxorubicin3821.2Doxorubicin +Taxane13776.5Adjuvant trasturumabYes3016.8Adjuvant hormonotherapyYes15284.9Adjuvant kadiotherapyYes17195.5Recurrence and localizationYes3217.9Iurog39.42.2Iurog39.42.5Final statusKes3217.9Kature and localizationYes3217.9Iurog39.43.6Iurog39.43.6Iurog39.43.6Iurog39.43.6Iurog39.43.6Iurog39.43.6Iurog39.43.6Iurog39.43.6Iurog39.43.6Iurog39.43.6Iurog39.43.6<	Lymphovascular invasion	Negative	73	40.8
T3-4 45 25.1 Lymph node removed Median (Min-Max) 15 (3-48) Metastatic lymph node Median (Min-Max) 3 (1-29) pN- stage 1-3 91 50.8 PN- stage 1-3 91 50.8 2NR 28 15.6 LNR 0.21 90 50.3 0.21-0.65 62 34.6 >0.65 27 15.1 Margin status Positive 9 5.0 Adjuvant Chemotherapy Doxorubicin 38 21.2 Doxorubicin +Taxane 137 76.5 Adjuvant trastuzumab Yes 30 16.8 Adjuvant hormonotherapy Yes 152 84.9 Adjuvant hormonotherapy Yes 32 17.9 Recurrence and localization Yes 32 17.9 Median (Min-Max) 3 9.4 15.5 Recurrence and localization Yes 32 17.9 Incoregional 3 9		Positive	106	59.2
Lymph node removed Median (Min-Max) 15 (3-48) Metastatic lymph node Median (Min-Max) 3 (1-29) pN- stage 1-3 91 50.8 4-9 60 33.5 210 28 15.6 LNR -20.2 90 50.3 0.21-0.65 62 34.6 0.21-0.65 62 34.6 -0.65 27 15.1 Margin status Positive 9 5.0 Adjuvant Chemotherapy Posorubicin 38 21.2 Doxorubicin +Taxane 137 76.5 15.1 Adjuvant trastuzumab Yes 30 16.8 Adjuvant bormonotherapy Yes 152 84.9 Adjuvant Radiotherapy Yes 32 17.9 Icocregional 3 9.4 15.5 Recurrence and localization Yes 32 17.9 Icocregional 3 9.4 15.6 Bone 20 62.5 15.9 <td>pT-stage</td> <td>T1-2</td> <td>134</td> <td>74.9</td>	pT-stage	T1-2	134	74.9
Metastatic lymph nodeMedian (Min-Max)3 (1-29)pN- stage1-39150.84-96033.52102815.6LNR0.219050.30.21-0.656234.6>0.652715.1Margin statusPositive950.1Adjuvant ChemotherapyDoxorubicin3821.2Doxorubicin +Taxane13776.512.1Taxane42.284.9Adjuvant trastuzumabYes3016.8Adjuvant hormonotherapyYes15284.9Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes3217.9Icoregional39.410.5Liver39.412.5Final statusExitus84.5		Т3-4	45	25.1
pN-stage 1-3 91 50.8 4-9 60 33.5 10 28 15.6 LNR -0.21 90 50.3 0.21-0.65 62 34.6 >0.65 27 15.1 Margin status Positive 9 5.0 Adjuvant Chemotherapy Doxorubicin 38 21.2 Doxorubicin +Taxane 137 76.5 Adjuvant trastuzumab Yes 30 16.8 Adjuvant trastuzumab Yes 30 16.8 Adjuvant trastuzumab Yes 30 16.8 Adjuvant trastuzumab Yes 152 84.9 Adjuvant kadiotherapy Yes 171 95.5 Recurrence and localization Yes 32 17.9 Icocregional 3 9.4 Lung 3 9.4 Lung 4 12.5 Brain 22 6.3	Lymph node removed	Median (Min-Max)	15 (3-48)	
Image: A-9 60 33.5 210 28 15.6 LNR <0.21	Metastatic lymph node	Median (Min-Max)	3 (1-29)	
≥10 28 15.6 LNR <0.21	pN- stage	1-3	91	50.8
LNR <0.21 90 50.3 0.210.65 62 34.6 >0.65 27 15.1 Margin status Positive 9 5.0 Adjuvant Chemotherapy Doxorubicin 38 21.2 Doxorubicin +Taxane 137 76.5 Taxane 4 2.2 Adjuvant trastuzumab Yes 30 16.8 Adjuvant hormonotherapy Yes 152 84.9 Adjuvant Radiotherapy Yes 171 95.5 Recurrence and localization Yes 32 17.9 Icooregional 3 9.4 Icoregional 3 9.4 Icung 4 12.5 Brain 2 6.3 Final status Exitus 8 4.5		4-9	60	33.5
0.21-0.656234.6>0.652715.1Margin statusPositive95.0Adjuvant ChemotherapyDoxorubicin3821.2Doxorubicin +Taxane13776.5Taxane42.2Adjuvant trastuzumabYes3016.8Adjuvant hormonotherapyYes15284.9Adjuvant hormonotherapyYes7650.0Adjuvant RadiotherapyYes7650.0Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes3217.9Icoregional39.412.5Iciver39.412.5Itiver39.412.5Final statusExitus84.5		≥10	28	15.6
>0.652715.1Margin statusPositive95.0Adjuvant ChemotherapyDoxorubicin3821.2Doxorubicin +Taxane13776.5Taxane42.2Adjuvant trastuzumabYes3016.8Adjuvant hormonotherapyYes15284.9Adjuvant hormonotherapyYes15284.9Adjuvant kadiotherapyYes7650.0Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes3217.9Iocoregional39.412.5Liver39.412.5Brain26.36.3Final statusExitus84.5	LNR	<0.21	90	50.3
Margin statusPositive95.0Adjuvant ChemotherapyDoxorubicin3821.2Doxorubicin +Taxane13776.5Taxane42.2Adjuvant trastuzumabYes3016.8Adjuvant hormonotherapyYes15284.9Adjuvant hormonotherapyYes7650.0Aromatase inhibitors7650.0100Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes3217.9Iocoregional39.412.5Liver39.412.5Evilon412.511.2Final statusExitus84.5		0.21-0.65	62	34.6
Adjuvant ChemotherapyDoxorubicin3821.2Doxorubicin +Taxane13776.5Taxane42.2Adjuvant trastuzumabYes3016.8Adjuvant hormonotherapyYes15284.9Tamoxifen7650.0Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes3217.9Icoregional39.4Bone2062.5Liver39.4Lung412.5Brain26.3Final statusExitus84.5		>0.65	27	15.1
Doxorubicin +Taxane 137 76.5 Taxane 4 2.2 Adjuvant trastuzumab Yes 30 16.8 Adjuvant hormonotherapy Yes 152 84.9 Tamoxifen 76 50.0 Adjuvant Radiotherapy Yes 76 50.0 Adjuvant Radiotherapy Yes 171 95.5 Recurrence and localization Yes 32 17.9 Icoregional 3 9.4 12.5 Bone 20 62.5 12.5 Liver 3 9.4 12.5 Brain 2 6.3 6.3 Final status Exitus 8 4.5	Margin status	Positive	9	5.0
Taxane42.2Adjuvant trastuzumabYes3016.8Adjuvant hormonotherapyYes15284.9Tamoxifen7650.0Aromatase inhibitors7650.0Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes3217.9Iocoregional39.46.5Liver39.412.5ExitusKaisa6.36.3Final statusExitus84.5	Adjuvant Chemotherapy	Doxorubicin	38	21.2
Adjuvant trastuzumabYes3016.8Adjuvant hormonotherapyYes15284.9Tamoxifen7650.0Adjuvant RadiotherapyYes7650.0Recurrence and localizationYes17195.5Iocoregional39.4Iver39.4Liver39.4ExitusKes2062.5Iter39.4Iter3 <td></td> <td>Doxorubicin +Taxane</td> <td>137</td> <td>76.5</td>		Doxorubicin +Taxane	137	76.5
Adjuvant hormonotherapyYes15284.9Tamoxifen7650.0Aromatase inhibitors7650.0Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes3217.9Icooregional39.462.5Liver39.412.5Lung412.563Final statusExitus84.5		Taxane	4	2.2
Tamoxifen7650.0Aromatase inhibitors7650.0Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes3217.9locoregional39.42062.5Bone2062.512.5Liver39.412.5Erain26.36.3Final statusExitus84.5	Adjuvant trastuzumab	Yes	30	16.8
Aromatase inhibitors7650.0Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes3217.9locoregional39.4Bone2062.5Liver39.4Lung412.5Brain26.3Final statusExitus84.5	Adjuvant hormonotherapy	Yes	152	84.9
Adjuvant RadiotherapyYes17195.5Recurrence and localizationYes3217.9locoregional39.4Bone2062.5Liver39.4Lung412.5Brain26.3Final status84.5		Tamoxifen	76	50.0
Recurrence and localizationYes3217.9locoregional39.4Bone2062.5Liver39.4Lung412.5Brain26.3Final status84.5		Aromatase inhibitors	76	50.0
Iocoregional 3 9.4 Bone 20 62.5 Liver 3 9.4 Lung 4 12.5 Brain 2 6.3 Final status 8 4.5	Adjuvant Radiotherapy	Yes	171	95.5
Bone2062.5Liver39.4Lung412.5Brain26.3Final status84.5	Recurrence and localization	Yes	32	17.9
Liver39.4Lung412.5Brain26.3Final status84.5		locoregional	3	9.4
Lung 4 12.5 Brain 2 6.3 Final status 8 4.5		Bone	20	62.5
Brain26.3Final statusExitus84.5		Liver	3	9.4
Final status Exitus 8 4.5		Lung	4	12.5
			2	6.3
Alive 171 95.5	Final status	Exitus	8	4.5
		Alive	171	95.5

BCS: Breast-conserving Surgery; HER2: Human Epidermal Growth Factor Receptor 2; ILC: Invasive Lobular Carcinoma; IDC: Invasive Ductal Carcinoma; LNR: Lymph Node Ratio; MRM: Modified Radical Mastectomy; pT: Pathologic Tumor Stage; pN: Pathologic Lymph Node Stage; SD: Standard Deviation; TNBC: Triple-Negative Breast Cancer

Variable		HR	95% CI for HR	р
Age (year)	Median	0.991	0.960-1.022	0.556
Menopausal status	Pre vs. Post	1.205	0.588-2.468	0.610
Surgical status	BCS vs. MRM	0.417	0.178-0.973	0.043
Hormone-Receptor Status	Negative vs. Positive	1.246	0.374-4.141	0.720
HER2-Status	Negative vs. Positive	2.669	1.049-6.785	0.039
TNBC	Yes vs. No	1.944	0.952-13.939	0.131
Histology	ILC vs. IDC	1.103	0.260-4.678	0.894
Stage	III vs. II	4.408	1.685-11.532	0.002
Grade	III vs. I+II	2.106	0.954-4.647	0.065
Perineural invasion	Negative vs. Positive	0.535	0.217-1.312	0.172
Lymphovascular invasion	Negative vs. Positive	0.854	0.418-1.741	0.664
pT-Stage	3+4 Vs 1+2	3.166	1.514-6.617	0.002
pN- Stage	1			<0.001
	2	2.246	0.686-7.346	0.181
	3	11.134	3.723-33.292	<0.001
Lymph Node Removed		1.000	0.955-1.047	0.997
Metastatic Lymph Node		1.089	1.029-1.152	0.003
LNR	<0.21			<0.001
	0.21-0.65	6.180	1.377-27.734	0.017
	>0.65	23.628	5.430-102.806	<0.001
Surgical Margin	Negative vs. Positive	0.656	0.088-4.867	0.680
Adjuvant Treatment	Doxorubicin			0.916
	Doxorubicin +taxane	0.948	0.437-2.055	0.893
	taxane	0.647	0.083-5.026	0.677
Adjuvant Trastuzumab	Yes vs No	0.364	0.143-0.922	0.033
Adjuvant Hormonotherapy	Yes vs No	0.726	0.274-1.920	0.518
Adjuvant Hormonotherapy	Aromatase inhibitors vs Tamoxifen	0.528	0.239-1.165	0.114
Adjuvant Radiotherapy	No vs Yes	1.350	0.318-5.717	0.683

Table 2. Univariate analysis for DFS

BCS: Breast-conserving Surgery; HER2: Human Epidermal Growth Factor Receptor 2; ILC: Invasive Lobular Carcinoma; IDC: Invasive Ductal Carcinoma; LNR: Lymph Node Ratio; MRM: Modified Radical Mastectomy; pT: Pathologic Tumor Stage; pN: Pathologic Lymph Node Stage; SD: Standard Deviation; TNBC: Triple-Negative Breast Cancer; DFS: Disease- free Survival

Table 3. Multivariate analysis for DFS

Variable		HR	95 % CI for HR	Р	
HER2-Status	Negative vs. Positive	4.641	1.614-13.340	0.004	
LNR	<0.21 (Ref.)	1		<0.001	
	0.21-0.65	6.996	1.545+31.660	0.012	
	>0.65	28.997	6.512-129.106	<0.001	
HER2: Human Enidermal Growth Factor Recentor 2: LNR: Lymph Node Ratio: DES: Disease-free Survival					

HER2: Human Epidermal Growth Factor Receptor 2; LNR: Lymph Node Ratio; DFS: Disease- free Survival

the patients with LNR> 0.65 (Figure 2).

LNR=0.21-0.65; however, it was 101 months (95% CI, 41-160.8) in In univariate analysis; type of surgery (BCS vs. MRM), HER-2 status (negative vs. positive), disease stage (III vs. II), pT stage, pN stage, num-




Figure 2. Overall Survival (OS) according to LNR groups

ber of positive ALN and LNR, and trastuzumab therapy were the predictive factors associated with DFS (p<0.05) (Table 2). The factors with $p\leq0.150$ identified in univariate analysis were then assessed in multivariate analysis with forward stepwise model. LNR and HER-2 status were found to be independent prognostic factors for DFS (p<0.05) (Table 3).

Discussion and Conclusion

In this study, we evaluated the prognostic value of LNR in ALN-positive BC patients with long term follow-up and real-life data. We demonstrated that the LNR can better predict tumor recurrence and survival than nodal staging in operated-stage II-III BC patients. The risk of recurrence almost increased by 30 folds in BC patients with LNR>0.65.

Danish Breast Cancer Cooperative Group Randomized Trials Subgroup Analysis evaluated the locoregional recurrence rate and survival regarding the number of positive ALN. In that analysis, the 15-year OS rates were observed to be 39% and 29% with and without radiotherapy, respectively. In the study, radiotherapy reduced the 15-year locoregional recurrence rate from 51% to 10% in patients with \geq 4 positive ALN and from 27% to 4% in those with 1-3 positive ALN. They concluded that the survival benefit after adjuvant radiotherapy was substantial and similar to patients with 1-3 positive ALN and \geq 4 positive ALN. However, in that study few lymph nodes were removed in most patients (median number of ALN resected was 7) (14). This situation may have affected the study results.

Nagao et al. (15) included 789 pN1-3 BC patients in whom the median number of ALN resected was 18.6 and reported that adjuvant radiotherapy did not significantly improve the outcomes. In another study, the median number of ALN resected was 23. In this study, the authors concluded that hormone receptor-positive patients treated by mastectomy and complete axillary dissection had a low risk of locoregional recurrence, even if four or more positive ALN were involved, thus, giving rise to doubts about the use of adjuvant radiotherapy in this subset of patients (16). These results suggest that sufficient number of ALN resected is helpful to reduce recurrence, hence affecting treatment decision-making in adjuvant radiotherapy.

In our study, the median number of ALN resected and the number of positive ALN was 15 and 3, respectively. Radiotherapy was given to

171 (95.5%) patients. Recurrence developed in 32 (17.9%) patients, only 3 (9.4%) of whom were locoregional. The lower rate of locoregional recurrence was due to the fact that almost all patients received adjuvant radiotherapy.

Kim et al. (17) performed a multicenter study with N1-stage BC patients and reported that high LNR was an independent prognostic factor for pN1 BC patients treated with BCS followed by adjuvant radiotherapy. It can also be helpful in deciding whether to irradiate supraclavicular lymph nodes in order to improve DFS. In a study designed by Wu et al. (13) including stage II-III BC patients who were not treated with adjuvant radiotherapy, it was reported that LNR was a better prognostic factor than pN staging in ALN positive BC. LNR should be used as an indication for adjuvant radiotherapy. Similarly, Ataseven et al. (18) reported that LNR was a prominent prognostic factor for survival and can potentially provide more information than the pN staging in different molecular subtypes of BC patients. In our study, the LNR is an independent prognostic factor of DFS and pN staging lost its significance when LNR was added to the multivariate analysis. These results suggest that LNR has a better prognostic value than pN staging.

Our study had some limitations. The study had a retrospective nature; hence, the results might be inherently flawed by selection bias. In addition, the number of samples was relatively low. Since it was a single-centered study, the outcomes may not reflect the results of a general population. However, most of the previous studies regarding this issue have enrolled only pN1-stage BC patients (8, 13, 17, 18), whereas our study also included pN1-3 stage BC patients.

In conclusion, our study showed that LNR was a better prognostic factor than nodal staging to predict recurrence and survival in stage II-III operated-BC patients. More importantly, the risk of recurrence almost increased by 30 folds in patients with LNR>0.65. However, there is no consensus on the optimal cut off value for LNR. Therefore, further prospective multicenter studies are required to assess the effect of LNR on prognosis in node-positive BC patients.

Ethics Committee Approval: Ethics committee approval was received for this study from the ethics committee of Yüzüncü Yıl University (22/05/2020-2020/03-54).

Informed Consent: The patients were not required to give informed consent for this study because the study utilized the anonymous retrospective data obtained after each patient accepted the treatment by a written consent.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – A.S., M.N.A.; Design – A.S., M.N.A.; Supervision – A.S., M.N.A.; Resources – A.S., M.N.A.; Materials – A.S., M.N.A.; Data Collection and/or Processing – M.N.A.; Analysis and/or Interpretation – A.S., M.N.A.; Literature Search – M.N.A.; Writing Manuscript – A.S.; Critical Review – A.S., M.N.A.; Other – A.S., M.N.A.

Conflict of Interest: The authors have no conflicts of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

References

 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30. (PMID: 31912902) [Crossref]

- Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ 2012; 344: e2718. (PMID: 22539013) [Crossref]
- Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-1241. (PMID: 12393820) [Crossref]
- Van de Steene J, Soete G, Storme G. Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. Radiother Oncol 2000; 55: 263-272. (PMID: 10869741) [Crossref]
- Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949-955. (PMID: 9395428) [Crossref]
- Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CML, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005; 97: 116-126. (PMID: 15657341) [Crossref]
- Truong PT, Woodward WA, Thames HD, Ragaz J, Olivotto IA, Buchholz TA. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 2007; 68: 59-65. (PMID: 17321065) [Crossref]
- Han TJ, Kang EY, Jeon W, Kim SW, Kim JH, Kim YJ, Park SY, Kim JS, Kim IA. The prognostic value of the nodal ratio in N1 breast cancer. Radiat Oncol 2011; 6: 131. (PMID: 21978463) [Crossref]
- Kuru B. Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. Eur J Surg Oncol 2006; 32: 1082-1088. (PMID: 16887320) [Crossref]
- Beenken SW, Urist MM, Zhang Y, Desmond R, Krontiras H, Medina H, Bland KI. Axillary lymph node status, but not tumor size, predicts

locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg 2003; 237: 732-739. (PMID: 12724640) [Crossref]

- Jang N, Choi JE, Kang SH, Bae YK. Validation of the pathological prognostic staging system proposed in the revised eighth edition of the AJCC staging manual in different molecular subtypes of breast cancer. Virchows Arch 2019; 474: 193-200. (PMID: 30474738) [Crossref]
- Vinh-Hung V, Verkooijen HM, Fioretta G, Neyroud-Caspar I, Rapiti E, Vlastos G, Deglise C, Usel M, Lutz JM, Bouchardy C. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol 2009; 27: 1062-1068. (PMID: 19164210) [Crossref]
- Wu SG, Chen Y, Sun JY, Li FY, Lin Q, Lin HX, He ZY. Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph nodepositive breast cancer patients treated with mastectomy without radiation therapy. Radiat Oncol 2013; 8: 119. (PMID: 23672513) [Crossref]
- Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&cc randomized trials. Radiother Oncol 2007; 82: 247-253. (PMID: 17306393) [Crossref]
- Nagao T, Kinoshita T, Tamura N, Hojo T, Morota M, Kagami Y. Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy. Int J Clin Oncol 2013; 18: 54-61. (PMID: 22068463) [Crossref]
- Gentilini O, Botteri E, Rotmensz N, Intra M, Gatti G, Silva L, Peradze N, Sahium RC, Gil LB, Luini A, Veronesi P, Galimberti V, Gandini S, Goldhirsh A, Veronesi U. Is avoiding post-mastectomy radiotherapy justified for patients with four or more involved axillary nodes and endocrineresponsive tumours? Lessons from a series in a single institution. Ann Oncol 2007; 18: 1342-1347. (PMID: 17693648) [Crossref]
- Kim J, Park W, Kim JH, Choi DH, Kim YJ, Lee ES, Shin KH, Kim JH, Kim K, Kim YB, Ahn SJ, Lee JH, Chun M, Lee HS, Kim JS, Cha J. Clinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study. Cancers (Basel) 2019; 11: 680. (PMID: 31100839) [Crossref]
- Ataseven B, Kummel S, Weikel W, Heitz F, Holtschmidt J, Lorenz-Salehi F, Kümmel A, Traut A, Blohmer J, Harter P, du Bois A. Additional prognostic value of lymph node ratio over pN staging in different breast cancer subtypes based on the results of 1,656 patients. Arch Gynecol Obstet 2015; 291: 1153-1166. (PMID: 25367604) [Crossref]